Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth Pharmaceuticals, a division of Wyeth and Progenics Pharmaceuticals have received a positive opinion for Relistor subcutaneous injection from the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency.
Subscribe to our email newsletter
The companies are seeking approval for Relistor in Europe for the treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.
The Committee for Medicinal Products for Human Use (CHMP) is responsible for reviewing medicinal product applications for safety, quality and efficacy. The CHMP’s positive opinion will now be forwarded to the European Commission for a final decision, which is anticipated by mid-2008.